Ocugen (OCGN) 8-K Ocugen Provides Business Update with First Quarter 2024 Financial Results

2

• • • • ® •

   4

5 Study Design • Patient with ≥8 years of age with Clinical and Molecular Diagnosis of Retinitis PigmentosaPopulation • BCVA ≤ 75 letters and ≥25 letters (ETDRS Chart) • Able to perform LDNA at ≤ 500 Lux but unable to pass the LDNA at ≤ 0.35 at the Screening visit • Presence of photoreceptors Key Eligibility Criteria Endpoints • Proportion of responder (LDNA ≥ 2 Lux Level from Baseline- Study Eyes) in treatment vs control armPrimary • Proportion of responder EYES (LDNA ≥ 2 Lux Level from Baseline) in treatment vs control • Proportion of responder (LLVA score change of 0.3logMAR from Baseline) in treatment vs control Secondary

6

   7

2  

• • • • • • ≈ • • • • • •

2  

• • • • • • • • 𝐦𝐦𝟐 • • • 𝐦𝐦𝟐 • • •

12

13

14

15 • • • • •